Narrow Your Search

Narrow Your Search

Focus

Publisher

Companies

People

Articles

7,133 Articles
Psychedelic Invest
Psychedelic Invest
/
Jul 26, 2024

Braxia Scientific Provides Update on Application for Management Cease Trade Order

Toronto, Ontario–(Newsfile Corp. – July 25, 2024) – Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) (“Braxia Scientific”, or the “Company”), today announced further to its press release of July 15, 2024, that the Ontario Securities Commission (the “OSC”) has...
Psychedelic Invest
Psychedelic Invest
/
Jul 26, 2024

Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference

SARASOTA, FL, July 26, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today...
Psychedelic Invest
Psychedelic Invest
/
Jul 26, 2024

Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) — Psyence Group Inc (“Psyence Group“) (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is pleased to announce that its NASDAQ-listed associate, Psyence Biomedical Ltd...
Psilocybin
Psychedelic Invest
Psychedelic Invest
/
Jul 25, 2024

Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally

Enveric Biosciences (NASDAQ: ENVB) (“Enveric”), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, today announced encouraging EB-003 preclinical results indicating the potential for the drug candidate to be delivered...
DMT
Psychedelics Today
Psychedelics Today
/
Jul 25, 2024

When Data Meets Doubt: Investigating the FDA Panel’s Rejection of MDMA

MAPS/Lykos’ MDMA trials for PTSD delivered overwhelmingly positive results. I thought that mattered until I sat through a nine-hour deliberation among the FDA’s Psychopharmacologic Drugs Advisory Committee on June 4, including two hours of public comments that skewed anti-Lykos.  After a long...
MDMA
Psychedelics Today
Psychedelics Today
/
Jul 25, 2024

Psychedelic Research: The Current Landscape and Future Directions

Join us for this free webinar with Blossom Founder, Floris Wolswijk, to gain an insider’s overview on the current landscape and future directions of psychedelic research. Where does microdosing and psychedelic-assisted therapy stand today across medical, underground, and religious pathways? What...
Microdose
Microdose
/
Jul 25, 2024

Enveric Biosciences Announces Promising Preclinical Results for EB-003

Preclinical Success Paves the Way for Clinical Trials by 2025 Enveric Biosciences, a forward-thinking biotechnology company specializing in neuroplastogenic treatments for neuropsychiatric disorders, has announced preclinical results that underscore the potential of their novel drug candidate,...
DMT
DoubleBlind Mag
DoubleBlind Mag
/
Jul 25, 2024

Tripping in the Trees: A Guide to Camping Safely With Psychedelics

Nature can be a powerful amplifier for psychedelic experiences. Gazing at a star-studded sky or feeling the wind brush against your skin can take your journey to a whole new level. But venturing into the wilderness under the influence of psychedelics requires extra planning and caution. This guide...
Psychedelics
Psychedelic Invest
Psychedelic Invest
/
Jul 25, 2024

Psyence Biomedical Ltd. Provides Update on Upcoming Phase IIb Trial

Psyence Biomedical Ltd. announced the export of nature-derived psilocybin to Australia and provided an update on its upcoming Phase IIb clinical trial evaluating nature-derived psilocybin as a potential treatment for Adjustment Disorder following an advanced cancer diagnosis in the Palliative Care...
Psychedelic Invest
Psychedelic Invest
/
Jul 25, 2024

The Many Use Cases for Psilocybin-Assisted Therapy

Psilocybin, a key compound in several species of hallucinogenic mushrooms, is at the forefront of the psychedelic renaissance. It has shown promise in treating various conditions such as anxiety, addiction, and depression. When ingested, psilocybin converts into psilocin, interacting with serotonin...
Psilocybin MDMA
Zen Habits
Zen Habits
/
Jul 25, 2024

Forcing Yourself to Do a Task vs. Letting Yourself Off the Hook

By Leo Babauta People often think, when they’re tired or don’t feel like doing a task (or a habit), that there are really only two choices: Force yourself to do the task anyway; orLet yourself off the hookAnd while there isn’t anything wrong with either of these choices, I’m here to remind...
DoubleBlind Mag
DoubleBlind Mag
/
Jul 25, 2024

Wellness Influencer Will Spend Eight Years in Prison for Human Trafficking

Kat Torres grew up in an impoverished Brazilian favela before finding fame as the model who partied with Leonardo DiCaprio. Then she drank ayahuasca after being introduced to it by her Hollywood friends. That’s when she “started going off the deep end.”  Torres gained a large social media...
Ayahuasca
Psychedelic Invest
Psychedelic Invest
/
Jul 24, 2024

Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced the export of nature-derived psilocybin to Australia and provided an update on its upcoming Phase IIb clinical trial evaluating nature-derived...
Psilocybin
Psychedelics - Green Market Report
Psychedelics - Green Market Report
/
Jul 24, 2024

RBC Capital launches coverage on Compass Pathways, cites $2.3B revenue potential

RBC Capital Markets initiated coverage on Compass Pathways (NASDAQ: CMPS) with an “Outperform” rating on Tuesday, citing the potential for $2.3 billion in peak revenues from its lead psilocybin-based therapy program. In a research note shared with Green Market Report, RBC analyst Leonid...
MDMA
DoubleBlind Mag
DoubleBlind Mag
/
Jul 24, 2024

Silent Epidemic: The Urban Indigenous Collective Takes Action for Missing Women, Girls, Trans, and Two-Spirit People

On May 5, dozens of Indigenous people and allies gathered at a pond in Central Park to observe the National Day of Awareness for Missing and Murdered Indigenous Women and Girls. They wore red, some with red-painted handprints pressed across their mouths. Chenae Bullock, a Shinnecock and Montauk...
Psychedelics
DoubleBlind Mag
DoubleBlind Mag
/
Jul 24, 2024

The Best Movies to Watch on Psychedelics, Depending on Your Vibe

There are a million things we can do while riding high on a trip. We can frolic gaily through the woods, get wild at a music festival or binge on finger paints and coloring books with our closest, most trusted psychonauts. Or, you can throw on a movie, sit back, and get sucked in.  But what’s...
Psychedelic Invest
Psychedelic Invest
/
Jul 24, 2024

Here’s How LSD Can Treat Depression

Psychedelic drugs such as psilocybin mushrooms and LSD have long been recognized for their potential to address some of the world’s most widespread mental health disorders. These substances are not only effective in treating conditions like treatment-resistant depression and PTSD but also offer...
LSD MDMA Psychedelics
Psychedelic Invest
Psychedelic Invest
/
Jul 23, 2024

Awakn Life Sciences Provides Update on Aminoindane New Chemical Entity Patent Portfolio

Toronto, Ontario–(Newsfile Corp. – July 22, 2024) – Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on...
Psychedelic Invest
Psychedelic Invest
/
Jul 23, 2024

Optimi Health to Enter Asian Market with PsiloThai Collaboration on Psilocybin Research

Vancouver, British Columbia–(Newsfile Corp. – July 23, 2024) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company“), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, is...
Psilocybin MDMA
DoubleBlind Mag
DoubleBlind Mag
/
Jul 23, 2024

A Guide to Identifying Liberty Cap Look-Alikes

When foraging for wild fungi, honing your identification skills is essential to ensure your safety. It should be noted that less than 1% of wild mushroom species are life-threateningly toxic to humans, and such species don’t tend to be particularly common (toxic plants being far more abundant)....
Psychedelic Invest
Psychedelic Invest
/
Jul 23, 2024

Reunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression

Reunion Neuroscience Inc. announced that the first patient has been dosed in the RECONNECT Phase 2 clinical trial of RE104 for the treatment of postpartum depression (PPD). RE104 was designed to be a safe, fast-acting, single-dose therapy to benefit patients suffering from underserved mental health...
Psychedelics Today
Psychedelics Today
/
Jul 23, 2024

Understanding Bad Trips: The Power and Potential of Adverse Psychedelic Experiences

What are bad trips, or adverse, negative, or challenging experiences? Can a definition truly define the power they have to create intense distress and sometimes life-defining moments? Why do they happen, and how do you deal with them? In this episode, Joe interviews Erica Rex, MA: award-winning...
Psychedelic Invest
Psychedelic Invest
/
Jul 23, 2024

Psilocybin’s Impact on Brain Activity

Psilocybin, the primary psychoactive compound found in hallucinogenic mushrooms, has long intrigued scientists and enthusiasts alike for its profound effects on perception and consciousness. Recent research conducted by the Washington University School of Medicine in St. Louis sheds new light on how...
DoubleBlind Mag
DoubleBlind Mag
/
Jul 23, 2024

Here’s How Psychedelics Legalization Is Unfolding In Colorado

Drug legalization is a fascinating experiment. It calls into focus societal systems to see how sturdy they are. Take Oregon, for instance. In 2020, it legalized the possession of all drugs. But by 2023-2024, the state made most drugs illegal again. Why? The main complaint was that “open-air drug...
Psychedelics
DoubleBlind Mag
DoubleBlind Mag
/
Jul 22, 2024

11 of the Best Quotes About Tripping and Nature

Picture this: you’re out in the woods, under a canopy of stars, and suddenly the trees seem to start whispering secrets. A river babbles on about the meaning of life, and the grass is doing a better job of grounding you than your yoga instructor.  In this article, we turn to a few notable...
Psychedelics
Psychedelic Invest
Psychedelic Invest
/
Jul 22, 2024

Therapeutic Potential of Psychedelics for Older Adults

Psychedelics such as DMT, LSD, and psilocybin have shown significant potential in treating affective symptoms across a variety of disorders. These substances induce altered states of consciousness characterized by intensified perceptions and emotions, which are linked to therapeutic benefits....
Psychedelics
DoubleBlind Mag
DoubleBlind Mag
/
Jul 22, 2024

GOP Congressman Slams FDA for Rejecting MDMA, Says Psychedelics Improved His Mental Health

In recent years, a quiet revolution has been unfolding within the realm of treatment for combat-related injuries: psychedelic therapies. Substances like MDMA, psilocybin, and ibogaine are now at the forefront of cutting-edge research for their potential to alleviate severe conditions, particularly...
Psilocybin MDMA Psychedelics
Psychedelics - Green Market Report
Psychedelics - Green Market Report
/
Jul 22, 2024

FDA expands warning on Diamond Shruumz as illnesses surge

The U.S. Food and Drug Administration has intensified its warning against Diamond Shruumz-brand products as reports of severe illnesses linked to the company’s edibles continue to climb. As of July 15, the FDA reports 69 illnesses across 28 states, with 36 hospitalizations and one death...
DoubleBlind Mag
DoubleBlind Mag
/
Jul 21, 2024

5 Trance Genres That Will Hypnotize Your Mind and Stimulate Your Soul

With or without substances, raving can put you into a trance. The hypnotizing beats of electronic music are conducive to flow states, deep reflection, and connecting the mind and body. The aptly named genre of trance especially aims to evoke such states, with strategically timed drops and peaks...
Psychedelic Invest
Psychedelic Invest
/
Jul 20, 2024

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

SARASOTA, FL, July 18, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today...
DoubleBlind Mag
DoubleBlind Mag
/
Jul 20, 2024

7 of the Trippiest Novels to Ever Grace the Page

Picking up a good book—whether we’re referring to blotter tabs or the written page—can kickstart a magical evening. Though reading and tripping may not go hand-in-hand, finishing a mind-twisting novel can feel just as psychedelic as dropping a hit or eating a cap or two.  Below, you’ll find...
Psychedelic Invest
Psychedelic Invest
/
Jul 20, 2024

HYTN Completes Acquisition of Prism Scientific Labs, Enhancing Psychedelic Compound Manufacturing Capabilities

VANCOUVER, British Columbia, July 19, 2024 (GLOBE NEWSWIRE) — HYTN Innovations Inc. (CSE: HYTN | FSE: 85W0) “HYTN” or “The Company”, a leader in the development, formulation, and manufacturing of psychoactive and psychotropic compounds, including cannabis and psilocybin, is pleased to...
Psychedelic Invest
Psychedelic Invest
/
Jul 20, 2024

Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product

Vancouver, Canada, July 19, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health...
Psychedelic Invest
Psychedelic Invest
/
Jul 20, 2024

Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SARASOTA, FL, July 19, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today...
DoubleBlind Mag
DoubleBlind Mag
/
Jul 19, 2024

“Quasi-Therapeutic” Use of Psychedelics Could Increase Harm, 2024 World Drug Report Says

The United Nations Office on Drugs and Crime (UNODC) released its 2024 World Drug Report — an annual publication that provides a comprehensive, data-informed overview of global drug trends. The report analyzes patterns in drug trafficking routes, drug production, and consumption worldwide, as well...
Psychedelics
DoubleBlind Mag
DoubleBlind Mag
/
Jul 19, 2024

10 of the Most Thought-Provoking DMT Quotes

DMT is unlike any other molecule. Not only does it produce extra-worldly states when smoked or ingested by drinking ayahuasca, but it also exists naturally in the body and is speculated to be behind transcendent phenomena like near-death experiences. It’s been called the “God molecule” due to...
DMT